Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: Results from the CORDELIA study

European Journal of Haematology

Volumn 95, Issue 3, 2015, Pages 244-253

  Aydinok, Yesim ^a   Porter, John B ^b   Piga, Antonio ^c   Elalfy, Mohsen ^d   El Beshlawy, Amal ^e   Kilinç, Yurdanur ^f   Viprakasit, Vip ^g   Yesilipek, Akif ^h   Habr, Dany ⁱ   Quebe Fehling, Erhard ⁱ   Pennell, Dudley J ^j  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e CAIRO UNIVERSITY   (Egypt)

^f CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^g MAHIDOL UNIVERSITY   (Thailand)

^h AKDENIZ UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Distribution; Heart; Iron; Liver; Prevalence; Thalassemia

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BETA THALASSEMIA MAJOR; BODY DISTRIBUTION; CARDIOMYOPATHY; CHELATION THERAPY; CHILD; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FAR EAST; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MULTICENTER STUDY; MYOCARDIAL IRON OVERLOAD; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; TRANSFUSION; TRANSFUSION DEPENDENT ANEMIA; ADVERSE EFFECTS; BLOOD TRANSFUSION; CARDIAC MUSCLE; CLINICAL TRIAL; COMPLICATION; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; PREVALENCE; TISSUE DISTRIBUTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; CHILD; DEFEROXAMINE; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; MYOCARDIUM; PREVALENCE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84938972782     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12487     Document Type: Article

References (40)

1. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-5.
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
3. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
5. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
6. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, Agus A, Angelucci E. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008;93:1385-8.
7. Carpenter J-P, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519-28.
8. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006;8:543-7.
9. Chouliaras GL, Kattamis A, Berdoukas V, Gotsis ED, Mavrogeni S, Ladis V. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Br J Haematol 2010;151:397-401.
10. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-8.
11. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-55.
12. Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. Magn Reson Med 2006;56:681-6.
13. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006;91:1388-91.
14. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006;23:662-8.
15. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
16. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, Wonke B, Walker JM, Pennell DJ. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging 2007;25:1147-51.
17. Pennell D, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica 2012;97:842-8.
18. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, De Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006;76:183-92.
19. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
20. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). Blood 2005;106:abst 3600.
21. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537-43.
22. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood 2014;123:1447-54.
23. Thomas AS, Garbowski M, Ang AL, Shah FT, Walker JM, Moon JC, Pennell DJ, Porter JB. A decade follow-up of a thalassemia major (TM) cohort monitored by cardiac magnetic resonance imaging (CMR): significant reduction in patients with cardiac iron and in total mortality. Blood 2010;116:abst 1011.
24. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
25. Voskaridou E, Ladis V, Kattamis A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 2012;91:1451-8.
26. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
27. Daar S, Pathare AV, Jain R, Zadjali SA, Pennell DJ. T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Haematologica 2009;94:140-1.
28. Aydinok Y, Bayraktaroglu S, Yildiz D, Alper H. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 2011;33:374-8.
29. Carpenter JP, Roughton M, Pennell DJ. International survey of T2* cardiovascular magnetic resonance in beta-thalassemia major. Haematologica 2013;98:1368-74.
30. El-Beshlawy A, El-Tagui M, Hamdy M, El Ghamrawy M, Azim KA, Salem D, Said F, Samir A, Pierre TS, Pennell DJ. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients. Ann Hematol 2013;93:375-9.
31. Viprakasit V, Gattermann N, Lee JW, Porter JB, Taher AT, Habr D, Martin N, Domokos G, Cappellini MD. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus 2013;11:108-22.
32. Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, Galanello R. Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment. Blood Cells Mol Dis 2013;51:142-5.
33. Brewer CJ, Coates TD, Wood JC. Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging 2009;29:357-64.
34. Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003;31:299-304.
35. Barton JC, Acton RT, Lee PL, West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 2007;39:206-11.
36. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006;84:349-64.
37. Lin H, Lian WS, Chen HH, Lai PF, Cheng CF. Adiponectin ameliorates iron-overload cardiomyopathy through the PPARalpha-PGC-1-dependent signaling pathway. Mol Pharmacol 2013;84:275-85.
38. Jensen PD. Evaluation of iron overload. Br J Haematol 2004;124:697-711.
39. Porter JB, Taher AT, Aydinok Y, Cappellini MD, Kattamis A, El-Ali A, Martin N, Pennell D. Impact of liver iron overload on myocardial T2* response in transfusion-dependent thalassemia major patients treated with deferasirox for up to 3 years. Blood 2013;122:abst 1016.
40. Lobo C, Angulo IL, Aparicio LR, Drelichman GI, Zanichelli MA, Cancado R. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload-the RELATH study. Hematology 2011;16:265-73.